BioCentury
ARTICLE | Finance

Europe: Maybe enough cash

April 2, 2001 7:00 AM UTC

1Q Financial Markets Review

Throughout Europe valuations have tumbled across the board, with BioCentury's London Index no longer defying gravity, and blue chip biotechs like Celltech Group plc (LSE:CCH; CCL, Slough, U.K.), Shire Pharmaceuticals Group plc (LSE:SHP; SHPGY, Basingstoke, U.K.) and Qiagen N.V. (NMarkt:QIA; QGENF, Venlo, the Netherlands) reflecting the general demise. While prices have bounced somewhat of late, the prospects aren't encouraging for cash-poor companies...